An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Trial Details

NCT ID

NCT05884255

Phase

PHASE3

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide
• long-acting Octreotide

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806
• Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

• Able and willing to provide a written informed consent;
• 18\~75 years old,male or female;
• ECOG performance status 0 or 1;
• Unresectable locally advanced or metastatic gastrointestinal neuroendocrine tumors (GEP-NETs) of low and medium grade (G1 or G2) confirmed by histo…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.